The Science Behind EpiEffect™

EpiEffect™, an innovative tri-layer human placental allograft developed by MiMedx, represents a significant advancement in the field of wound care management. Designed to address both acute and chronic wounds, EpiEffect™ utilizes a lyophilized membrane that includes the amnion, intermediate, and chorion layers. This unique structure provides a protective barrier that supports the body’s natural healing mechanisms. Rich in over 300 regulatory proteins, EpiEffect™ delivers a biocompatible Extracellular Matrix (ECM) crucial for effective wound healing. For more information on EpiEffect™, download the Product Brochure.

Versatility and Ease of Use: The EpiEffect™ Advantage

EpiEffect™ is designed for ease of use, offering the ability to be easily applied and repositioned after hydration. It is compatible with various treatments, such as compression therapy, Negative Pressure Wound Therapy (NPWT), and Hyperbaric Oxygen Therapy (HBOT), making it a versatile option in wound care protocols. Its five-year shelf life and terminal sterilization process ensure safety and convenience for healthcare professionals.

The clinical applications of EpiEffect™ are extensive, effectively treating a range of wound types, including acute, chronic, post-debridement, and dehisced wounds, as well as specific conditions like Diabetic Foot Ulcers (DFUs), Venous Leg Ulcers (VLUs), and Pressure Ulcers (PUs). This broad efficacy underscores its role in enhancing wound healing outcomes. Additional information on product application can be found Here or by contacting your local MiMedx representative. 

Navigating Reimbursement for EpiEffect™

For healthcare providers, the reimbursement for EpiEffect™ is equally impressive, facilitating high-quality patient care without the financial strain. This is part of WoundGenex’s dedication to offering high-tier, cutting edge, accessible wound care solutions, further establishing our leadership in the sector through our exclusive collaboration with MiMedx.

The reimbursement landscape for EpiEffect™ is quite favorable, with comprehensive coverage from Medicare, and a growing acceptance among Medicaid and commercial insurance plans. Currently, the reimbursement rate is set at $527.995 per square centimeter under code Q4278. WoundGenex specializes in MiMedx product reimbursements through our Premier Graft Program and Wound Care Revenue Cycle Management (RCM) services, ensuring healthcare providers can maximize their reimbursement for EpiEffect™.

By aligning with WoundGenex’s Premier Graft Program, healthcare providers can rest assured that they are partnering with a leader in wound care management dedicated to advancing the field through both quality of patient care and robust financial support. Reach out to WoundGenex or your regional MiMedx representative to learn more!

For more information on EpiEffect™, contact WoundGenex Sales or MiMedx directly.